- Home
- GRFS vs HAE Comparison
GRFS vs HAE Comparison
Compare GRFS & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRFS
- HAE
- Stock Information
- Founded
- GRFS 1940
- HAE 1971
- Country
- GRFS Spain
- HAE United States
- Employees
- GRFS 23737
- HAE N/A
- Industry
- GRFS Biotechnology: Pharmaceutical Preparations
- HAE Medical/Dental Instruments
- Sector
- GRFS Health Care
- HAE Health Care
- Exchange
- GRFS Nasdaq
- HAE Nasdaq
- Market Cap
- GRFS 5.5B
- HAE 4.4B
- IPO Year
- GRFS 2006
- HAE 1991
- Fundamental
- Price
- GRFS $8.05
- HAE $82.10
- Analyst Decision
- GRFS Sell
- HAE Strong Buy
- Analyst Count
- GRFS 2
- HAE 9
- Target Price
- GRFS $10.50
- HAE $108.78
- AVG Volume (30 Days)
- GRFS 1.3M
- HAE 494.4K
- Earning Date
- GRFS 01-01-0001
- HAE 02-06-2025
- Dividend Yield
- GRFS N/A
- HAE N/A
- EPS Growth
- GRFS N/A
- HAE N/A
- EPS
- GRFS 0.27
- HAE 2.41
- Revenue
- GRFS $7,814,096,584.00
- HAE $1,361,223,000.00
- Revenue This Year
- GRFS $8.86
- HAE $7.63
- Revenue Next Year
- GRFS $7.00
- HAE $4.40
- P/E Ratio
- GRFS $35.12
- HAE $33.82
- Revenue Growth
- GRFS 7.21
- HAE 9.84
- 52 Week Low
- GRFS $5.30
- HAE $70.25
- 52 Week High
- GRFS $12.15
- HAE $97.97
- Technical
- Relative Strength Index (RSI)
- GRFS 51.40
- HAE 46.23
- Support Level
- GRFS $7.29
- HAE $80.65
- Resistance Level
- GRFS $7.85
- HAE $85.00
- Average True Range (ATR)
- GRFS 0.33
- HAE 2.21
- MACD
- GRFS 0.06
- HAE -0.66
- Stochastic Oscillator
- GRFS 77.22
- HAE 18.03
About GRFS Grifols S.A.
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
About HAE Haemonetics Corporation
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.